Literature DB >> 2434377

Phenotypic differentiation of aphidicolin-selected human neuroblastoma cultures after long-term exposure to nerve growth factor.

L M Jensen.   

Abstract

Human neuroblastoma SH-SY5Y (SY5Y) cultures, exposed to murine 7 S nerve growth factor (NGF) for 5 weeks and selected with aphidicolin (Aph) for 1 week, acquire several properties indicative of mature peripheral nerve cells. The mitotic activity of treated cultures decreases prior to Aph selection and ultimately reaches a level approximately 3% that of untreated cultures by Week 4 of treatment. The measured plasma membrane resting potential of the cells increases from -5 mV for untreated cells to -(45-56) mV for NGF/Aph-treated cells. Intracellular stores of monoamines are increased as determined by histochemical staining, and levels of neuron-specific enolase antigen increase as a result of NGF/Aph treatment. The resulting outgrowth of neurites is extensive and large bundles of processes commonly exceed 300 micron in length. NGF/Aph-treated cells acquire a dependence upon NGF for survival; however, with continued administration of NGF, the cultures appear to be capable of surviving indefinitely. Retinoic acid will also promote certain aspects of a differentiated phenotype under similar culture conditions. As judged by these criteria, cells of the SY5Y human neuroblastoma cell line have the potential for phenotypic and irreversible differentiation in vitro and can survive for prolonged periods under these culture conditions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2434377     DOI: 10.1016/0012-1606(87)90103-5

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  9 in total

1.  The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells.

Authors:  W Poluha; D K Poluha; B Chang; N E Crosbie; C M Schonhoff; D L Kilpatrick; A H Ross
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  Effects of gamma-IFN and NGF on subpopulations in a human neuroblastoma cell line: flow cytometric and morphological analysis.

Authors:  J Ridge; D A Terle; E Dragunsky; I Levenbook
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

3.  The reverse transforming effects of nerve growth factor on five human neurogenic tumor cell lines: in vitro results.

Authors:  M J Yaeger; A Koestner; K Marushige; Y Marushige
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Immunohistochemical localization of Trk receptor protein in pediatric small round blue cell tumors.

Authors:  M J Donovan; B L Hempstead; C Horvath; M V Chao; D Schofield
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

5.  The use of nerve growth factor as a reverse transforming agent for the treatment of neurogenic tumors: in vivo results.

Authors:  M J Yaeger; A Koestner; K Marushige; Y Marushige
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

6.  A reduced rate of bulky DNA adduct removal is coincident with differentiation of human neuroblastoma cells induced by nerve growth factor.

Authors:  L Jensen; S Linn
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

7.  Serum from patients with type 2 diabetes with neuropathy induces complement-independent, calcium-dependent apoptosis in cultured neuronal cells.

Authors:  S Srinivasan; M J Stevens; H Sheng; K E Hall; J W Wiley
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 8.  Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation.

Authors:  E Abemayor; N Sidell
Journal:  Environ Health Perspect       Date:  1989-03       Impact factor: 9.031

Review 9.  Neuroprotective Effects of Bioactive Compounds and MAPK Pathway Modulation in "Ischemia"-Stressed PC12 Pheochromocytoma Cells.

Authors:  Adi Lahiani; Annette Brand-Yavin; Ephraim Yavin; Philip Lazarovici
Journal:  Brain Sci       Date:  2018-02-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.